Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21788090 | 0.95 | ADRB2 (0.33) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL24064985 | 0.91 | ADRB2 (0.31) | ADRB2ADRB1ADRB3 | |
| SCHEMBL24117766 | 0.88 | KDM4E (0.35) | — | |
| SCHEMBL23900916 | 0.87 | ADRB2 (0.31) | ADRB2ADRB1ADRB3 | |
| SCHEMBL23418290 | 0.87 | ADRB2 (0.33) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL21788259 | 0.83 | ADRB2 (0.32) | ADRB2ADRB1ADRB3 | |
| SCHEMBL13059476 | 0.76 | ADRB2 (0.32) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL23418071 | 0.76 | ADRB2 (0.50) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL12122746 | 0.76 | ADRB2 (0.50) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL19542989 | 0.75 | ADRB2 (0.31) | ADRB2ADRB1ADRB3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | ADRB2 3526/4885ADRB1 2961/4885ADRB3 4452/4885 |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, TEK, BTN3A1 | ADRB2 4067/4885ADRB1 3861/4885ADRB3 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.